Literature DB >> 24365373

Neurologic aspects of plasma cell disorders.

Urszula Sobol1, Patrick Stiff2.   

Abstract

Plasma cell disorders make up a broad spectrum of diseases that are characterized by the appearance of an abnormal clone of plasma cells, which typically manifests as a production of monoclonal immunoglobulin protein (monoclonal gammopathy). The overproduction of plasma cells and subsequent monoclonal gammopathy may be malignant or a premalignant process. Monoclonal gammopathy of undetermined significance (MGUS) is an example of a benign process with a malignant potential. Multiple myeloma, Waldenström macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, and AL amyloidosis (immunoglobulin light chain amyloidosis) are examples of malignant plasma cell disorders which require treatment. Neurologic manifestations of an underlying plasma cell disorder can be variable and typically challenging to treat. They can range from mild symptoms resulting from therapy to treat the disorder to clinically significant and life-threatening complications related to the disease itself. The peripheral nervous system is more commonly affected than the central nervous system. Peripheral neuropathy is a frequent manifestation and is associated with all of the plasma cell disorders (MGUS, multiple myeloma, POEMS syndrome, Waldenström macroglobulinemia and AL amyloidosis) with notable differences in the signs and symptoms among the different groups. Examples of central nervous system manifestations include spinal cord pathology, such as spinal cord compression from vertebral collapse or plasmacytoma. Intracranial involvement is rare but can occur from brain parenchyma infiltration, leptomeningeal involvement, and tumor-like lesions, such as amyloidoma in AL amyloidosis and plasmacytoma in multiple myeloma. Encephalopathy can occur due to metabolic disturbances related to the underlying plasma cell disorder, including hypercalcemia and uremia in multiple myeloma and hyperviscosity in Waldenström macroglobulinemia. Included in this chapter is a detailed discussion of the various plasma cell disorders and their spectrum of neurologic manifestations.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MGUS; Plasma cell disorder; amyloidosis; encephalopathy; multiple myeloma; neurologic manifestations; peripheral neuropathy; plasmacytoma

Mesh:

Substances:

Year:  2014        PMID: 24365373     DOI: 10.1016/B978-0-7020-4087-0.00073-5

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  7 in total

1.  Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Authors:  Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal:  Cancer Immunol Res       Date:  2018-11-05       Impact factor: 11.151

2.  Smoldering Multiple Myeloma Associated Leukoencephalopathy Presenting with Holmes Tremor, Ataxia, and Pyramidal Syndrome.

Authors:  Camila Catherine Aquino; Barbara Connolly; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2018-07-19

3.  An unusual cause of anemia and encephalopathy.

Authors:  Sanjeev Kumar Sharma; Dharma Choudhary; Anil Handoo; Gaurav Dhamija; Gaurav Kharya; Vipin Khandelwal; Mayank Dhamija; Sweta Kothari
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-01       Impact factor: 2.576

4.  Abducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial Plasmacytoma.

Authors:  Elochukwu Ibekwe; Neil B Horsley; Lan Jiang; Nadine-Stella Achenjang; Azubuogu Anudu; Zeeshan Akhtar; Karina G Chornenka; Gregory P Monohan; Yevgen G Chornenkyy
Journal:  J Clin Med       Date:  2018-09-03       Impact factor: 4.241

5.  Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.

Authors:  Syeda Saba Kareem; Neena Viswanathan; Solmaz Sahebjam; Nam D Tran; Tyra Gatewood; Katherine Tobon; Rachid Baz; Yolanda Piña; Kenneth H Shain; Sepideh Mokhtari
Journal:  Onco Targets Ther       Date:  2022-09-06       Impact factor: 4.345

6.  Hypercalcemic Encephalopathy as an Initial Presentation of Multiple Myeloma.

Authors:  Durga Shankar Meena; Gopal Krishana Bohra; Mahendra Kumar Garg; Abhishek Purohit; Deepak Kumar; Swapnil Tripathi
Journal:  Case Rep Emerg Med       Date:  2020-02-08

7.  Collet-Sicard syndrome due to concurrent extramedullary intracranial plasmacytoma and jugular venous sinus thrombosis in multiple myeloma.

Authors:  Dilraj Singh Sokhi; Caroline Wangui Mithi; Farah Alnoor Ebrahim; Adil Salyani; Sheila Waa; Malkit Singh Riyat
Journal:  Clin Case Rep       Date:  2021-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.